Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 8/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.46 |
| ▸ | MCHR2 | Q969V1 | 2/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.42 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.42 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.42 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23258577 | 0.92 | MCHR1 (0.56) | MCHR1EPHX2HTR2CMCHR2HDAC3 | |
| SCHEMBL20481503 | 0.89 | MCHR1 (0.49) | MCHR1EPHX2HTR2CMCHR2HDAC3 | |
| SCHEMBL18038061 | 0.88 | MCHR1 (0.57) | MCHR1EPHX2HTR2CMCHR2HDAC3 | |
| SCHEMBL19900321 | 0.86 | EPHX2 (0.52) | MCHR1EPHX2HTR2CMCHR2HDAC3 | |
| SCHEMBL18037967 | 0.86 | EPHX2 (0.52) | MCHR1EPHX2HDAC3HDAC4HDAC1 | |
| SCHEMBL23258565 | 0.86 | EPHX2 (0.52) | MCHR1EPHX2HDAC3HDAC4HDAC1 | |
| SCHEMBL23258581 | 0.86 | MCHR1 (0.45) | MCHR1EPHX2HTR2CMCHR2HDAC3 | |
| SCHEMBL18038013 | 0.85 | EPHX2 (0.51) | MCHR1EPHX2HDAC3HDAC4HDAC1 | |
| SCHEMBL18038060 | 0.85 | EPHX2 (0.51) | MCHR1EPHX2HTR2CMCHR2HDAC3 | |
| SCHEMBL25858525 | 0.85 | SLC2A1 (0.51) | MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | Curtana Pharmaceuticals, Inc. | 2023-08-31 | — | — | US | disclosed |
| US-11691951-B2 | Inhibition of Olig2 activity | Curtana Pharmaceuticals, Inc. (US) | 2023-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691951-B2 | Inhibition of Olig2 activity | GLI2, ING2, GMFG | MCHR1 4146/4885EPHX2 294/4885HTR2C 3524/4885 |
| US-20230271926-A1 | INHIBITION OF OLIG2 ACTIVITY | GLI2, ING2, GMFG | MCHR1 4146/4885EPHX2 294/4885HTR2C 3524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.